Previous close | 0.8000 |
Open | 0.8000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 50.00 |
Expiry date | 2024-10-18 |
Day's range | 0.8000 - 0.8000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on Thursday, June 6 in New York City. John Houston, Ph.D., Chairperson, Chief Executive Officer and President, and Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, will participate
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 clinical trial with vepdegestrant, a novel investigational oral PROteolysis Targeting Chimera (PROTAC®) ER degrader, in combination with Pfizer’s atirmociclib (PF-07220060), an investigational CDK4 inhibitor, were accepted for presentation at the 2024 American Society of Clinical Oncology Annual Congre
Key Insights Arvinas' Annual General Meeting to take place on 29th of May CEO John Houston's total compensation...